Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 2/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | KLRK1 | P26718 | 1/20 | 0.34 |
| ▸ | MICA | Q29983 | 1/20 | 0.34 |
| ▸ | RAET1L | Q5VY80 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | GRN | P28799 | 1/20 | 0.33 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.33 |
| ▸ | KRAS | P01116 | 1/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19321650 | 0.86 | GABRA1 (0.33) | RAPGEF4PDE2AGABRA1GABRB1TDP1 | |
| SCHEMBL24673443 | 0.84 | TACR1 (0.35) | RAPGEF4PDE2AAHRP2RX3TACR1 | |
| SCHEMBL437277 | 0.84 | TACR1 (0.42) | RAPGEF4PDE2ATACR1S1PR1ALDH1A1 | |
| SCHEMBL10629252 | 0.84 | TACR1 (0.39) | PDE2AGABRA1TACR1S1PR1ALDH1A1 | |
| SCHEMBL16959193 | 0.84 | RAPGEF4 (0.39) | RAPGEF4PDE2AAHRNOTUMKLRK1 | |
| SCHEMBL17069226 | 0.84 | RAPGEF4 (0.39) | RAPGEF4PDE2AAHRNOTUMKLRK1 | |
| SCHEMBL17069227 | 0.84 | RAPGEF4 (0.39) | RAPGEF4PDE2AAHRNOTUMKLRK1 | |
| SCHEMBL28672817 | 0.84 | TACR1 (0.42) | RAPGEF4PDE2AAHRTACR1KRAS | |
| SCHEMBL630804 | 0.84 | PDE2A (0.47) | RAPGEF4PDE2AAHRNOTUMKLRK1 | |
| SCHEMBL28672819 | 0.84 | TACR1 (0.42) | RAPGEF4PDE2AAHRTACR1KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024145369-A1 | COMPOUNDS FOR TREATMENT OF HAIR LOSS | PELAGE PHARMACEUTICALS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| US-20240208968-A1 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | DICE MOLECULES SV, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20230322753-A1 | HETEROARYL DERIVATIVE, METHOD FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | VORONOI INC. (KR) | 2023-10-12 | — | — | US | disclosed |
| EP-3860987-B1 | PESTICIDALLY ACTIVE BENZENE- AND AZINE-AMIDE COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2023-07-19 | — | — | EP | disclosed |
| EP-3752498-B1 | SOMATOSTATIN MODULATORS AND USES THEREOF | CRINETICS PHARMACEUTICALS INC (US) | 2023-06-28 | — | — | EP | disclosed |
| EP-3867237-B1 | PESTICIDALLY ACTIVE AZOLE-AMIDE COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2023-06-07 | — | — | EP | disclosed |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KUMQUAT BIOSCIENCES INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230143596-A1 | PESTICIDALLY ACTIVE DIAZINE-BISAMIDE COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2023-05-11 | — | — | US | disclosed |
| US-20230143596-A1 | PESTICIDALLY ACTIVE DIAZINE-BISAMIDE COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2023-05-11 | — | — | US | disclosed |
| US-20230124361-A1 | SMALL MOLECULE STING ANTAGONISTS | CURADEV PHARMA PVT. LTD. (IN) | 2023-04-20 | — | — | US | disclosed |
| US-9006265-B2 | Substituted fused pyrimidinones and dihydropyrimidinones | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-9006265-B2 | Substituted fused pyrimidinones and dihydropyrimidinones | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-20150045332-A1 | Novel Sphingosine 1-Phosphate Receptor Antagonists | ARROYO BIOSCIENCES L.L.C. | 2015-02-12 | — | — | US | disclosed |
| US-8304403-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-06 | — | — | US | disclosed |
| US-20120157306-A1 | Substituted Fused Pyrimidinones and Dihydropyrimidinones | BAYER CROPSCIENCE AG (DE) | 2012-06-21 | — | — | US | disclosed |
| US-20120157306-A1 | Substituted Fused Pyrimidinones and Dihydropyrimidinones | BAYER CROPSCIENCE AG (DE) | 2012-06-21 | — | — | US | disclosed |
| US-20100267669-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-21 | — | — | US | disclosed |
| WO-2009116577-A1 | PROCESSES FOR PRODUCTION OF 1-(SUBSTITUTED PHENYL)-1- SUBSTITUTED SILYL ETHERS, ALCOHOLS OR KETONES, AND INTERMEDIATES | 日産化学工業株式会社 (JP) | 2009-09-24 | — | — | WO | disclosed |
| WO-2008076041-A1 | AZETIDINAZABICYCLO [3.2.1] OCTAN DERIVATIVES THAT ARE NEUROKININ (NK) RECEPTOR ANTAGONISTS AND THEIR USE. | ALBIREO AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008076042-A1 | AZETIDINPIPERAZINE DERIVATIVES THAT ARE NEUROKININ (NK) RECEPTOR ANTAGONISTS AND THEIR USE. | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208968-A1 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | ITGB1, ITGA1, ITGAV | RAPGEF4 1671/4885PDE2A 2058/4885AHR 4664/4885 |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KRAS, NRAS, BRAF | RAPGEF4 498/4885PDE2A 2982/4885AHR 1931/4885 |
| US-20150045332-A1 | Novel Sphingosine 1-Phosphate Receptor Antagonists | S1PR2, S1PR1, S1PR5 | RAPGEF4 340/4885PDE2A 2313/4885AHR 1883/4885 |
| US-20230143596-A1 | PESTICIDALLY ACTIVE DIAZINE-BISAMIDE COMPOUNDS | DDT, ACHE, NIT2 | RAPGEF4 3036/4885PDE2A 136/4885AHR 1879/4885 |
| US-20120157306-A1 | Substituted Fused Pyrimidinones and Dihydropyrimidinones | DHPS, FDPS, DPYD | RAPGEF4 2093/4885PDE2A 2251/4885AHR 1551/4885 |
| US-20230124361-A1 | SMALL MOLECULE STING ANTAGONISTS | STING1, CGAS, MAVS | RAPGEF4 471/4885PDE2A 580/4885AHR 3862/4885 |
| US-20100267669-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | RAPGEF4 3925/4885PDE2A 2430/4885AHR 2476/4885 |
| US-20230322753-A1 | HETEROARYL DERIVATIVE, METHOD FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | ERBB4, ERBB2, ERBB3 | RAPGEF4 1365/4885PDE2A 4754/4885AHR 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.